MiNK Therapeutics, Inc.
NASDAQ:INKTBiotechnology
Healthcare
$10.22 -2.87%
-$0.35 today
- Market cap
- $52.17M
- Beta
- 0.47
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.60
52W Low $6.80High $76.00
Volume 0.01M
Average 0.05M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$5.93M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$14.72M
FY 2025 · Annual
+36.1% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.21M) | (27.99M) | (22.46M) | (10.78M) | (12.49M) |
| Depreciation & Amortization | 77.96K | 121.75K | 204.62K | 215.44K | 181.75K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.74M | 3.03M | 3.86M | 1.81M | 2.67M |
| Change in Working Capital | 3.74M | 8.77M | 2.9M | 459.73K | 3.29M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (152.04K) | 2.66M | (1.92M) | (1.18M) | 689.71K |
| Other Working Capital | 3.89M | 6.11M | 4.81M | 1.64M | 2.6M |
| Other Non-Cash Items | 11.83M | (2.79M) | (266.78K) | (1.26M) | 424.63K |
| Operating Cash Flow | (12.83M) | (18.87M) | (15.76M) | (9.56M) | (5.93M) |
| Capital Expenditures | (248.98K) | (250.05K) | (73.56K) | (4) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (248.98K) | (250.05K) | (73.56K) | 0 | 0 |
| Debt Repayment | 9.46M | 0 | 0 | 5M | 0 |
| Common Stock Issued | 39.8M | 0 | 0 | 5.8M | 14.9M |
| Common Stock Repurchased | 0 | (157.19K) | (477.64K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 150 | 1.6K | 70.47K | 19.99K | (173.35K) |
| Financing Cash Flow | 49.26M | (155.6K) | (407.17K) | 10.82M | 14.72M |
| Effect of Forex Changes | 16.9K | 19.39K | (25.25K) | (54.7K) | (13.43K) |
| Net Change in Cash | 36.2M | (19.25M) | (16.27M) | 1.21M | 8.78M |
| Free Cash Flow | (13.08M) | (19.12M) | (15.84M) | (9.56M) | (5.93M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$12.5M
+ D&A$181.7K
+ Stock-Based Comp$2.7M
+ Deferred Tax$0
+ Working Capital$3.3M
+ Other Non-Cash$424.6K
= Operating Cash Flow-$5.9M
- Capex$0
= Free Cash Flow-$5.9M
Analysis
FY2025 free cash flow is -$5.9M. FCF conversion is 47.4% of net income. Operating cash flow was -$5.9M, with capex of $0. The largest bridge item is Working Capital at $3.3M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 14, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 |
Does INKT generate free cash flow?
MiNK Therapeutics, Inc. (INKT) generated -$5.93M of free cash flow in fiscal 2025.
How much operating cash flow does INKT produce?
Operating cash flow was -$5.93M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.